Profile data is unavailable for this security.
About the company
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.
- Revenue in AUD (TTM)5.91m
- Net income in AUD-13.25m
- Incorporated1975
- Employees0.00
- LocationDimerix Ltd425 Smith Street, FitzroyMELBOURNE 3065AustraliaAUS
- Phone+61 30081-3321
- Fax+61 89388-8256
- Websitehttps://dimerix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kintor Pharmaceutical Ltd | 2.26m | -34.32m | 240.08m | 136.00 | -- | 4.86 | -- | 106.39 | -0.4417 | -0.4417 | 0.029 | 0.552 | 0.0194 | 10.66 | 1.06 | 74,768.20 | -29.53 | -47.72 | -44.54 | -55.96 | -55.12 | -36.16 | -1,521.00 | -8,974.73 | 0.4222 | -33.76 | 0.2881 | -- | -- | -- | 85.36 | -- | -53.11 | -- |
| Unicocell Biomed Co Ltd | 1.55m | -4.79m | 245.29m | 44.00 | -- | 7.19 | -- | 158.45 | -1.79 | -1.79 | 0.5794 | 11.97 | 0.0432 | 1.57 | 14.29 | 785,909.10 | -13.36 | -19.69 | -13.71 | -20.61 | 67.65 | 66.04 | -309.55 | -558.76 | 33.60 | -- | 0.0805 | -- | 29.66 | 15.17 | -10.66 | -- | -35.54 | -- |
| Wuhan YZY Biopharma Co Ltd | 29.79m | -16.03m | 252.12m | 106.00 | -- | -- | -- | 8.46 | -0.4604 | -0.4604 | 0.8554 | -0.1619 | 0.5805 | 11.54 | 13.96 | 1,467,423.00 | -31.24 | -- | -133.35 | -- | 63.96 | -- | -53.82 | -- | 0.9019 | -24.38 | 1.21 | -- | -- | -- | 49.09 | -- | -- | -- |
| Dimerix Ltd | 5.91m | -13.25m | 285.19m | 0.00 | -- | 21.25 | -- | 48.22 | -0.0239 | -0.0239 | 0.0106 | 0.0224 | 0.096 | -- | 22.53 | -- | -21.50 | -48.20 | -27.12 | -68.49 | -- | -- | -224.08 | -932.89 | -- | -- | 0.0072 | -- | 913.54 | 365.69 | 22.39 | -- | -- | -- |
| Immunotech Biopharm Ltd | 0.00 | -45.92m | 303.95m | 173.00 | -- | -- | -- | -- | -0.4567 | -0.4567 | 0.00 | -0.291 | 0.00 | -- | -- | 0.00 | -37.04 | -36.20 | -186.73 | -45.67 | -- | -- | -- | -- | 0.0712 | -6.63 | 1.48 | -- | -- | -- | 44.18 | -- | 5.95 | -- |
| Mabpharm Ltd | 87.09m | -5.65m | 318.57m | 383.00 | -- | 15.69 | 47.57 | 3.66 | -0.0076 | -0.0076 | 0.1176 | 0.0274 | 0.4209 | 0.4659 | 4.05 | 1,539,030.00 | -2.73 | -19.62 | -4.02 | -25.69 | 86.40 | -- | -6.48 | -211.59 | 0.6906 | -1.58 | 0.7552 | -- | 196.27 | -- | 38.89 | -- | -12.13 | -- |
| ImmuneOnco Biopharmaceuticls Shanghi Inc | 23.03m | -62.18m | 321.70m | 195.00 | -- | 2.76 | -- | 13.97 | -0.8799 | -0.8799 | 0.3256 | 1.50 | 0.148 | -- | 3,865.48 | 821,755.80 | -40.09 | -- | -51.56 | -- | -- | -- | -270.79 | -- | -- | -- | 0.2236 | -- | 19,109.59 | -- | 16.76 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Schr�der Equities GmbHas of 28 Nov 2025 | 830.00k | 0.14% |
| Mandarine Gestion SAas of 30 Jun 2025 | 240.00k | 0.04% |
| Wilson Asset Management (International) Pty Ltd.as of 30 Jun 2025 | 0.00 | 0.00% |
